Catalog No.	PA007270.m1
Product Name	Anti CD19 Monoclonal Antibody (SJ25C1) | PA007270.m1
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3
Clone	SJ25C1.
Isotype	Mouse IgG1 kappa.
Source/Host	The anti-human CD19 monoclonal antibody (clone: SJ25C1) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: SJ25C1) specifically binds to the human CD19 protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD19 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: SJ25C1), Mouse IgG1 Kappa is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007270.m1: Recombinant Anti-human CD19 Monoclonal Antibody (Clone: SJ25C1), Mouse IgG1 Kappa, In vivo Grade

Recombinant mouse IgG1 Monoclonal Antibody.

Background of nti-human CD19 Monoclonal Antibody (Clone: SJ25C1)

The SJ25C1 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References of Anti-human CD19 Monoclonal Antibody:

1、Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies.
Poirot, L., et al. Cancer Res. 2015 Sep;75(18):3853-3864. doi: 10.1158/0008-5472.CAN-14-3321. PMID: 26183927
“We provide proof of concept for the general application of this approach by manufacturing a TCR/CD52-deficient CD19 CAR T cell (dKO-CART19). …The manufacturing platform is highly reproducible, thus suitable for use in the large-scale manufacturing of CAR T-cell products directed against arbitrary targets for administration as “off-the-shelf” immunopharmaceuticals. …CD19 CARs were cloned into a commercial lentiviral vector backbone downstream from an EF1α promoter and concentrated lentiviral vectors were produced by Vectalys. …All injections were via tail vein. For antitumor activity, 6- to 8-week old NSG mice were injected with tumor cells and later, at the indicated time, with engineered or control T cells. …Translocation events between CD52 and TRAC loci were detected by quantitative PCR (qPCR) using primers described in Online Supplementary Methods.”

2、Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.
Smeltzer, J. P., et al. Clin Cancer Res. 2014 Jun;20(11):2862-2872. doi: 10.1158/1078-0432.CCR-13-2367. PMID: 24727328
“To differentiate different PD1+ cells such as exhausted effector T cells and T follicular helper cells (TFH) cells, PD1+ cells were costained with CD3, CD19, CXCR5, and TIM3. …Briefly, tonsils obtained from routine tonsillectomy were cut into small pieces and incubated for 1 hour at 37° with constant shaking in RPMI media containing 90 μg/mL gentamicin, 2 mg/mL collagenase (Worthington Biochemical), and 0.1 mg/mL DNase (Sigma). …CD19+ cells were isolated from lymphoma samples by positive selection and cultured with FDCs at a ratio of 2.5:1. At 48 hours, viability of CD19+ cells was determined by the percentage of B cells that were negative by flow cytometry for Annexin V and propidium iodide. …There were 58 patients with follicular lymphoma that later transformed to DLBCL. …The median estimated follow-up for still alive patients (n = 15) was 22.5 years, whereas the median OS for the entire cohort was 9.2 years.”

3、TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.
Hegde, M., et al. Mol Ther Nucleic Acids. 2013 Jul 9;2(7):e105. doi: 10.1038/mtna.2013.32. PMID: 23839099
“The extracellular domain of the TanCAR was designed to include a CD19-specific single chain antibody variable fragment (scFv) followed by a Gly-Ser linker, a HER2-specific scFv (FRP5) and another Gly-Ser tandem repeat hinge. …Predictive molecular modeling was used to interrogate the hypothetical TanCAR structure and provide rational basis for constructing a potentially functional molecule. …From the in silico docking of these molecules, it appeared that the potential interactions of TanCAR with the target molecules could accommodate the intended bispecificity, and as such, we used this arrangement as an initial model to explore the ability of TanCAR to interact with the target molecules individually. …The modeled design of the TanCAR extracellular domain, composed of the CD19- and HER2-scFv fragments in tandem and separated by a linker, was assembled on Clone Manager, modified to introduce desired and remove unwanted restriction enzyme sites and optimized for maximum protein production using GeneOptimizer software. …Specific detection of the juxta-membrane HER2-scFv confirmed that the surface expression of the TanCAR extracellular domain in its entirety.”

4、Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Bernett, M. J., et al. Cancer Res. 2008 Oct 1;68(19):8049-8057. doi: 10.1158/0008-5472.CAN-08-2268. PMID: 18829563
“CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. …Consequently, some patients do not respond to rituximab, and many of those that respond will relapse. …Although early clinical studies with murine unconjugated CD19 antibodies showed safety and responses in individual patients, these responses were not durable. …Here, we describe the characterization of XmAb5574, a humanized anti-CD19 antibody with increased FcγR binding that has highly enhanced ADCC against multiple NHL and leukemia cell lines and primary ALL and mantle cell lymphoma (MCL) tumor cells. …Peripheral blood samples were obtained from healthy volunteers or from male patients with ALL or MCL expressing high levels of CD19.”

5、A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases.
Boyles, J. S., et al. JCI Insight. 2023 Jul 10;8(13):e166137. doi: 10.1172/jci.insight.166137. PMID: 37427592
“In addition to being an attractive antigen for B cell targeting, CD19 has been previously described to play a role in the regulation of the B cell response. …Here we describe an anti-CD19 B cell–inhibiting, nondepleting antibody LY3541860. …Moreover, anti-mCD19 nondepleting antibody demonstrated improved efficacy over anti-CD20 B cell–depleting antibodies in different mouse B cell–dependent autoimmune disease models. …The initial Fab hit from phage panning, C323, was confirmed by ELISA using the CD19 extracellular domain (ECD) protein, converted to IgG4, and then was confirmed to bind CD19 on cells by FACS using both Daudi human Burkitt’s lymphoma cell line and primary human B cells. …These data are summarized in Table 1 and demonstrate both the high affinity of LY3541860 for CD19 as well as the potential for significantly increased apparent affinity to cell-surface CD19 due to avidity from bivalent engagement.”

6、Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors.
Zheng, Q., et al. Mol Oncol. 2017 May;11(5):584-594. doi: 10.1002/1878-0261.12056. PMID: 28306193
“To construct the single-chain foldback diabody CD19 immunotoxin, it is needed to build a modified scFv (FMC63) with a short linker (one G4S) between VL and VH. …In vitro efficacy of the CD19 immunotoxins was assessed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega, cat# G7571) to human CD19+ mantle cell lymphoma cell line JeKo-1. …The breeding pairs of NSG mice were purchased from Jackson laboratories (Bar Harbor, Maine) and bred in our rodent barrier facilities. …All animals were injected IV with 10 million of human CD19+ mantle cell lymphoma cells (JeKo-1) via the tail vein. …The CD19 immunotoxins were captured using a Ni-Sepharose fast flow resin and further purified using strong anion-exchange resin.”

7、Generation and characterization of avian-derived anti-human CD19 single chain fragment antibodies.
Tsai, K. C., et al. Anim Biotechnol. 2019 Oct;30(4):293-301. doi: 10.1080/10495398.2018.1486323. PMID: 30261812
“The human cluster of differentiation 19 (CD19) is highly expressed in most leukemia, rendering is a promising therapeutic target. …In this study, we generated anti-CD19 single-chain variable fragments (scFv) from immunized chickens by phage display technology. …After constructing a scFv antibody library with 2.5 × 108 compositional diversity for panning, one representative scFv clone S2 which can specifically recognize to the CD19 protein was isolated and characterized. …Compared with the chicken germline, hyper mutation in the complementarity-determining regions (CDRs) suggested that scFv S2 could be generated through an antigen-driven humoral response. …Furthermore, the characteristics of chicken antibodies of a protein database were investigated.”

8、MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.
Gallagher, S., et al. Arthritis Rheumatol. 2016 Apr;68(4):965-976. doi: 10.1002/art.39503. PMID: 26606525
“These findings highlight the ability of MEDI-551 to deplete B cells and ASCs in autoimmune Sle1.hCD19-Tg mice. …Thus, the novel ability of MEDI-551 to remove a broad range of B cells as well as to lower most disease-driving autoantibodies in an autoimmune disease mouse model warrants continued research. …MEDI-551 treatment of Sle1.hCD19-Tg mice resulted in effective and sustained B cell depletion throughout the duration of the experiment. …The numbers of B cells in the blood, spleen, and bone marrow were determined by flow cytometry assay. …Serum autoantibody and total immunoglobulin levels were determined by enzyme-linked immunosorbent assay, and levels of inflammatory proteins were tested using a multianalyte profiling platform.”

For more references about Anti-human CD19 Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry

Anti-human CD19 (SJ25C1) from: Anti-human CD19 Monoclonal Antibody (Clone: SJ25C1): PA007270.m1 Syd Labs

No more offers for this product!